Focus on citalopram: A selective reuptake inhibitor for the treatment of depression

Citalopram is a selective serotonin reuptake inhibitor (SSRI) approved by the FDA for the treatment of major depression. Pharmacologically, it has higher serotonin selectivity than other marketed SSRIs. Clinical trials in a variety of practice settings and depressed populations show citalopram to be effective and well tolerated. The drug lacks significant side effects commonly noted with tricyclic antidepressants, such as orthostatic hypotension. Its adverse effect profile is similar to those of other SSRIs, with nausea most commonly reported. Currently, few drug interactions have been documented with citalopram. Some data suggest that citalopram inhibits the cytochrome P450 isoenzyme system, particularly the 2D6 isoenzyme, less potently than the other SSRIs do. As such, it decreases the potential for drug interactions, making it an appealing option for treating depression in primary care and in the elderly.

Duke Scholars

Author P. Murali Doraiswamy Psychiatry & Behavioral Sciences, Behavioral Medicine & Neur ...